Supernus Announces Third Quarter 2013 Earnings Conference Call and Webcast
ROCKVILLE, Md., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals,
Inc. (Nasdaq:SUPN), today announced that the Company expects to report
financial results for the quarter ended September 30, 2013 after the market
closes on Tuesday November 12, 2013. Supernus will host a conference call at
5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to review the financial
results, as well as provide an update on other business matters of the
A live webcast will be available at www.supernus.com. The webcast will be
archived on the Company's website for 30 business days following the live
Callers should dial in approximately 10 minutes prior to the start of the
call. The phone number to join the conference call is +1(877) 288-1043 (U.S.
and Canada) or +1 (970) 315-0267 (international and local). The access code
for the live call is 92928553.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on developing and commercializing products for the treatment of central
nervous system, or CNS, diseases. The Company has two marketed products for
the treatment of epilepsy, Oxtellar XR^TM (extended release oxcarbazepine),
and Trokendi XR^TM (extended release topiramate). The Company is also
developing several product candidates in psychiatry to address large market
opportunities in ADHD including ADHD patients with impulsive aggression. These
product candidates include SPN-810 for impulsive aggression in ADHD and
SPN-812 for ADHD.
CONTACT: Jack Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
Press spacebar to pause and continue. Press esc to stop.